护城河对比
最多三家已覆盖的公司，逐项对照。每一项判断都是人工编辑的判断，而非公司披露的数字——并且每一项都附有其引用依据。
| Marvell Technology | IBM | Tempus AI | |
|---|---|---|---|
| 护城河评级 | 窄 FY2026 10-K (filed 2026-03-11): differentiated platform IP — over 10,000 issued patents and pending applications as of 2026-01-31, plus a proven custom ASIC platform leveraging ultra-high-speed SerDes, silicon photonics, co-packaged optics and custom HBM — but Marvell itself calls its markets 'intensely competitive' with 'pricing pressures', notes customers 'have chosen to develop certain semiconductor products internally', and discloses two >=10% customers with the ten largest at 82% of FY2026 net revenue. Real, defensible IP in a concentrated, contestable customer base = narrow, not wide. https://www.sec.gov/Archives/edgar/data/1835632/000183563226000011/mrvl-20260131.htm | 窄 IBM's FY2025 10-K describes "a highly competitive environment" with "hundreds of competitors" and says IBM is "regularly exposed to new competitors" as it executes its hybrid-cloud/AI strategy, while differentiating through "incumbency with enterprises" and "client relationships and trust" — a real but narrow moat, not a wide one. | 窄 The FY2025 10-K documents a real asset: a network "connected in some way to more than 55% of all oncologists practicing in the United States" and "more than 65% of all academic medical centers," via "more than 700 unique data connections" across "more than 5,000 healthcare institution sites," with "broad data rights, including the rights to longitudinally updated data." Not eroding: revenue $693.4M to $1,271.8M (+83%), net loss narrowed from $705.8M to $245.0M. Not wide: still loss-making against "an accumulated deficit of $2.4 billion," with payment received on only "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests." |
| 护城河类型 | 无形资产与知识产权 The moat rests on hard-to-replicate mixed-signal IP: the 10-K describes the custom ASIC platform built on ultra-high-speed SerDes, ARM compute, security, storage, silicon photonics and advanced packaging (die-to-die interconnects, chiplets, CPO, custom HBM), with multiple 5nm designs executed, 3nm in progress and a 2nm platform in development; a secondary switching-cost element comes from multi-year custom design wins co-developed to individual customer specifications. https://www.sec.gov/Archives/edgar/data/1835632/000183563226000011/mrvl-20260131.htm | 转换成本 The 10-K roots IBM's differentiation in "incumbency with enterprises" and "client relationships and trust" — installed-base lock-in across its hybrid-cloud platform (Red Hat) and enterprise software and infrastructure raises switching costs. | 网络效应 The filing states the mechanism: "Each product line is designed to enable and enhance the other, thereby creating network effects." That is the filing's own characterisation, so the rating rests on corroborating facts: 700+ data connections across 5,000+ sites with longitudinal rights; roughly 801,000 tests in FY2025 (about 340,500 Oncology) feeding the records Insights licenses; Insights working with "19 of the 20 largest public pharmaceutical companies based on 2024 revenue" at "approximately 126%" net revenue retention. Intangibles fit less well: the xT PMA, ADLT status, Paige's clearance and five CAP/CLIA labs are real, but named peers hold comparable approvals. |
| 领先地位 | 并列领先者 Leader in its optics niche, #2 in custom silicon: ~60% of high-end PAM4 DSP share (36kr, 2026-06-27, https://eu.36kr.com/en/p/3870758441178373) but an estimated 20-25% of custom AI ASIC design services versus Broadcom's ~70% (hashrateindex, 2026-05-13, https://hashrateindex.com/blog/design-partners-ai-asic-market-part-2/) — net, a co-leader in AI data-center connectivity/custom silicon behind Broadcom overall. | 快速追随者 An enterprise incumbent that differentiates via "incumbency with enterprises" but is "regularly exposed to new competitors" in its hybrid-cloud/AI push (FY2025 10-K) — a follower in the current AI cycle rather than its leader. | 势均力敌 The filing claims no ranked lead; its positional language is hedged, as in "one of the largest sequencers of cancer patients... in the United States." Two disclosures cut the other way: the reimbursement goal is to become "more in line with other NGS providers who have adopted similar strategies, such as FMI and Guardant," and competitors "may have longer operating histories; larger customer bases; greater brand recognition and market penetration." Competition names Foundation Medicine (Roche), Caris, Guardant, Natera, Neogenomics, Quest, LabCorp, Flatiron, IQVIA, ConcertAI and major CROs, all unranked. Scaled positions on both sides support parity, not a top position. |
| 定价权 | 中等 The 10-K characterizes Marvell's markets as having 'pricing pressures' and intensifying competition (https://www.sec.gov/Archives/edgar/data/1835632/000183563226000011/mrvl-20260131.htm), yet the Q1 FY2027 release reports 52.1% GAAP / 58.9% non-GAAP gross margin on record revenue (https://www.sec.gov/Archives/edgar/data/1835632/000183563226000014/q127_8kx522026ex-991.htm) — differentiated-IP margins, tempered by hyperscaler buyer power. | 中等 Gross margin is high and rising (54.9% FY2021 to 58.2% FY2025) on a software-mix shift, but "price" is a principal method of competition per the 10-K and consulting/infrastructure remain price-competitive. | 弱 Diagnostics prices are administered: after a CPT code is set, "CMS, establish payment levels and coverage rules under Medicare," delegating to MACs, while "Private payers establish their rates and coverage rules independently." Average revenue per Oncology test rose from about $1,510 to about $1,600, "driven primarily by increased Medicare reimbursement rates" — the payer moved the price. Collection came on "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests," and payer "cost-saving initiatives... are likely to result in pricing pressures." The moderate pocket is confined to Data and applications ($316.4M of $1,271.8M). |
| 综述 | Marvell is a fabless data-infrastructure silicon supplier whose center of gravity has shifted decisively to the AI data center: the data center end market was $6,100.3M, 74% of FY2026 revenue, up from 40% two fiscal years earlier (FY2026 10-K). Its strongest position is electro-optics — in high-end PAM4 optical DSPs for 400G+ transceivers it holds roughly 60% share on Inphi-inherited SerDes/FEC IP, with Broadcom above 30%, the two together over 90% (36kr, 2026-06-27). In custom AI silicon it is the structural #2 design partner at an estimated 20-25% of the custom AI ASIC design-services market versus Broadcom's ~70%, anchored by AWS Trainium and Microsoft Maia wins (hashrateindex, 2026-05-13). The Q1 FY2027 release (2026-05-27) shows the flywheel turning — record $2.418B revenue (+28% YoY), Q2 guided to $2.7B mid-point (+35% YoY), management citing 'exceptional AI-related bookings' across 800G/1.6T optics, 51.2T switches, CPO/NPO and custom XPU — and the Celestial AI (Photonic Fabric) and XConn (PCIe/CXL switching) acquisitions closed in February 2026 extend the interconnect moat toward scale-up fabrics. The offsets that keep the moat narrow are in Marvell's own filing: intense competition (AMD, Alchip, Astera, Ayar, Broadcom, Credo, GUC, Lightmatter and others), hyperscaler in-housing risk, and heavy customer concentration. | IBM's moat rests on deep enterprise incumbency — sticky installed-base relationships across hybrid cloud (Red Hat), enterprise software, and mission-critical infrastructure, plus brand and a large patent base. But its own FY2025 10-K frames "a highly competitive environment" with "hundreds of competitors" and says IBM is "regularly exposed to new competitors" as it pursues hybrid cloud and AI, so the moat is durable but narrow and contested in the AI/cloud growth arena. | Tempus AI's durable asset is an installed provider network and the longitudinal data rights attached to it, not any single assay: connections to more than 55% of practicing U.S. oncologists and more than 65% of academic medical centers, 700+ data connections across 5,000+ institution sites. That network makes the linked clinical-molecular database sellable — Insights serves 19 of the 20 largest public pharmaceutical companies by 2024 revenue at roughly 126% net revenue retention, and the trial network (1,400+ trials signed, 40,000+ patients identified) depends on the sequencing base. Economics are improving: revenue up 83% to $1.27B, net loss down from $705.8M to $245.0M. It stops short of wide on the filing's own terms — a $2.4B accumulated deficit, payment on only ~55% of oncology and ~50% of hereditary tests, and Diagnostics prices set by CMS, MACs and private payers. |
| 产业链位置 | Fabless supplier spanning 'data center core to network edge': it sits between hyperscaler AI compute (custom XPU/XPU-attach ASICs) and the optical layer (PAM4/coherent DSPs, CPO/LPO, DCI, AEC, PCIe retimers), outsourcing fabrication to independent CMOS foundries; the Feb-2026 Celestial AI and XConn acquisitions push it further into scale-up photonic fabric and PCIe/CXL/UALink switching (FY2026 10-K, https://www.sec.gov/Archives/edgar/data/1835632/000183563226000011/mrvl-20260131.htm). | A hybrid-cloud platform, enterprise-AI (watsonx), and consulting provider to large enterprises — a software/cloud layer of the AI stack. | Tempus sits between clinical care and pharma R&D. It ingests data from 5,000+ institution sites, runs five CAP/CLIA labs (Chicago, Atlanta, Raleigh, Aliso Viejo, Minneapolis via OneOme), and sells Diagnostics to providers and payers ($955.4M FY2025, +111%, administered) and Data and applications to pharma ($316.4M, +31%, negotiated). The clinical output is the data business's input. |
| 产品（份额 / 壁垒） |
|
|
|
| 长周期投票 | +0.13 权重 0.20 · 群体判断 bullish 编辑先验，未经回测。 | +0.06 权重 0.20 · 群体判断 bearish 编辑先验，未经回测。 | -0.01 权重 0.20 · 群体判断 neutral 编辑先验，未经回测。 |